# Assessment of Physical Activity During Therapy With Regorafenib for Metastatic Colorectal Cancer

> **NCT02347852** · — · COMPLETED · sponsor: **Bayer** · enrollment: 25 (actual)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** Regorafenib (Stivarga, BAY73-4506)

## Key facts

- **NCT ID:** NCT02347852
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-20
- **Primary completion:** 2016-09-08
- **Final completion:** 2016-09-08
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2018-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02347852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02347852, "Assessment of Physical Activity During Therapy With Regorafenib for Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02347852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*